Avacopan

Drug Profile

Avacopan

Alternative Names: CCX 168

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Mario Negri Institute for Pharmacological Research
  • Class Anti-inflammatories; Cyclopentanes; Piperidines; Small molecules
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-neutrophil cytoplasmic antibody-associated vasculitis; Glomerulonephritis; Haemolytic uraemic syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Phase II Haemolytic uraemic syndrome; IgA nephropathy
  • Phase I Autoimmune disorders
  • Clinical Phase Unknown Glomerulonephritis

Most Recent Events

  • 22 Mar 2017 Clinical trials in Glomerulonephritis in USA (PO)
  • 22 Mar 2017 Avacopan receives Orphan Drug status for Glomerulonephritis in USA
  • 13 Mar 2017 ChemoCentryx terminates a phase II trial for Haemolytic uraemic syndrome in Italy, as the trial accomplished its goal with the enrolled six patients (PO) (NCT02464891)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top